World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
122
Citations
54126
World Ranking
3481
National Ranking
1915

Thomas A. Buchholz publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Thomas A. Buchholz sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 725 publications — 83rd percentile

83% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Thomas A. Buchholz D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Thomas A. Buchholz sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 122 D-Index — 83rd percentile

83% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Thomas A. Buchholz is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research primarily focuses on oncology, with a significant contribution to medicine, particularly in breast cancer treatment and related fields.

The main fields of study for Buchholz include:

  • Medicine

Within medicine, their subfields of study highlight a specialization in:

  • Oncology
  • Cancer Research
  • Pathology and Forensic Medicine
  • Surgery
  • Radiology, Nuclear Medicine and Imaging

The key topics Buchholz has explored encompass:

  • Breast Cancer Treatment Studies
  • Global Cancer Incidence and Screening
  • Lymphoma Diagnosis and Treatment
  • Breast Lesions and Carcinomas
  • Chronic Lymphocytic Leukemia Research
  • Breast Implant and Reconstruction
  • Advances in Oncology and Radiotherapy

Among recent publications associated with Buchholz, the following are notable:

  • Multidisciplinary Management of Locoregional Recurrent Breast Cancer, 2020, Journal of Clinical Oncology

Other recent works in the broader research environment include:

  • Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer, 2020, JAMA Oncology
  • Five-Year Longitudinal Analysis of Patient-Reported Outcomes and Cosmesis in a Randomized Trial of Conventionally Fractionated Versus Hypofractionated Whole-Breast Irradiation, 2021, International Journal of Radiation Oncology*Biology*Physics
  • Neoadjuvant Chemotherapy and Immunotherapy for Estrogen Receptor-Positive Human Epidermal Growth Factor 2-Negative Breast Cancer, 2024, Journal of Clinical Oncology
  • Organophotocatalytic Aerobic Oxygenation of Phenols in a Visible-Light Continuous-Flow Photoreactor, 2021, Chemistry - A European Journal

Buchholz has frequently collaborated with researchers such as:

  • Kelly K. Hunt
  • Bruce G. Haffty
  • Dirk Klingbiel
  • Joana Parreira
  • Kai Hübel

Their work has appeared predominantly in several scientific venues, including:

  • Journal of Clinical Oncology
  • International Journal of Radiation Oncology*Biology*Physics
  • Practical Radiation Oncology
  • HemaSphere
  • Orthopaedic Proceedings

Best Publications

  • Future of Cancer Incidence in the United States: Burdens Upon an Aging, Changing Nation

    Benjamin D. Smith;Grace L. Smith;Arti Hurria;Gabriel N. Hortobagyi

  • Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer

    Aman U. Buzdar;Nuhad K. Ibrahim;Deborah Francis;Daniel J. Booser

  • Clinical Course of Breast Cancer Patients With Complete Pathologic Primary Tumor and Axillary Lymph Node Response to Doxorubicin-Based Neoadjuvant Chemotherapy

    Henry M. Kuerer;Lisa A. Newman;Terry L. Smith;Fred C. Ames

  • Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer: The ACOSOG Z1071 (Alliance) Clinical Trial

    Judy C. Boughey;Vera J. Suman;Elizabeth A. Mittendorf;Gretchen M. Ahrendt

  • Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO).

    Benjamin D. Smith;Benjamin D. Smith;Douglas W. Arthur;Thomas A. Buchholz;Bruce G. Haffty

  • American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer

    Harold J. Burstein;Ann Alexis Prestrud;Jerome Seidenfeld;Holly Anderson

  • Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update

    Harold J. Burstein;Harold J. Burstein;Sarah Temin;Holly Anderson;Thomas A. Buchholz

  • WNT/β-catenin mediates radiation resistance of mouse mammary progenitor cells

    Wendy A. Woodward;Mercy S. Chen;Fariba Behbod;Maria P. Alfaro

  • Cyclin E and Survival in Patients with Breast Cancer

    Khandan Keyomarsi;Susan L. Tucker;Thomas A. Buchholz;Matthew Callister

  • Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors

    Valentina Guarneri;Kristine Broglio;Shu Wan Kau;Massimo Cristofanilli

  • Neoadjuvant Therapy with Paclitaxel followed by 5-Fluorouracil, Epirubicin, and Cyclophosphamide Chemotherapy and Concurrent Trastuzumab in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: An Update of the Initial Randomized Study Population and Data of Additional Patients Treated with the Same Regimen

    Aman U. Buzdar;Vicente Valero;Nuhad K. Ibrahim;Deborah Francis

  • Risk of Cardiac Death After Adjuvant Radiotherapy for Breast Cancer

    Sharon Hermes Giordano;Yong Fang Kuo;Jean L. Freeman;Thomas A Buchholz

  • Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.

    W. Fraser Symmans;Caimiao Wei;Rebekah Gould;Xian Yu

  • Incidence, Treatment Costs, and Complications of Lymphedema After Breast Cancer Among Women of Working Age: A 2-Year Follow-Up Study

    Ya-Chen Tina Shih;Ying Xu;Janice Nicole Cormier;Sharon Hermes Giordano

  • High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller.

    Ana Maria Gonzalez-Angulo;Jennifer K Litton;Kristine R Broglio;Funda Meric-Bernstam

  • International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment

    S. Dawood;S. D. Merajver;P. Viens;P. B. Vermeulen

  • Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer.

    Roman Rouzier;Radhika Rajan;Peter Wagner;Kenneth R. Hess

  • Locoregional Recurrence Patterns After Mastectomy and Doxorubicin-Based Chemotherapy: Implications for Postoperative Irradiation

    Angela Katz;Eric A. Strom;Thomas A. Buchholz;Howard D. Thames

  • Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience.

    Allen M. Chen;Funda Meric-Bernstam;Kelly K. Hunt;Howard D. Thames

  • Invasive Lobular Carcinoma Classic Type: Response to Primary Chemotherapy and Survival Outcomes

    Massimo Cristofanilli;Ana Gonzalez-Angulo;Nour Sneige;Shu Wan Kau

Frequent Co-Authors

Gabriel N. Hortobagyi
Gabriel N. Hortobagyi The University of Texas MD Anderson Cancer Center
Wendy A. Woodward
Wendy A. Woodward The University of Texas MD Anderson Cancer Center
Kelly K. Hunt
Kelly K. Hunt The University of Texas MD Anderson Cancer Center
Henry Mark Kuerer
Henry Mark Kuerer The University of Texas MD Anderson Cancer Center
Sharon H. Giordano
Sharon H. Giordano The University of Texas MD Anderson Cancer Center
Funda Meric-Bernstam
Funda Meric-Bernstam The University of Texas MD Anderson Cancer Center
Massimo Cristofanilli
Massimo Cristofanilli Cornell University
Aysegul A. Sahin
Aysegul A. Sahin The University of Texas MD Anderson Cancer Center
Vicente Valero
Vicente Valero The University of Texas MD Anderson Cancer Center
Aman U. Buzdar
Aman U. Buzdar The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in medicine but seeking different or supplementary paths, there are many flexible online degrees related to healthcare. For example, pursuing an online degree in nutrition can lead to rewarding roles in dietetics, wellness coaching, and public health. These programs are ideal for those passionate about food sciences and preventive health.

Healthcare administration is another key area with growing demand. The best mha programs online are designed for professionals aiming to lead hospitals, clinics, or healthcare agencies, providing core leadership and management skills.

For registered nurses seeking advancement without the traditional in-person requirements, some rn to bsn programs no clinicals exist, allowing completion through online coursework. These programs are especially convenient for working professionals.

For those interested in advanced practice and leadership in nursing, accelerated dnp programs online offer a fast-track option to earn a Doctorate of Nursing Practice, opening opportunities in education, administration, or clinical leadership.

Best Scientists Citing Thomas A. Buchholz

Trending Scientists